In the PEERLESS trial (PEERLESS; 32 Down), the difference was driven by less clinical deterioration and/or bailout as well as less use of intensive care for those treated with the FlowTriever system ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback